shine-logo

Mo-99

Home » Mo-99

SHINE Europe B.V. Designing Advanced Medical Isotopes Facility in the Netherlands

A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.

2022-02-01T17:57:14-06:00February 2, 2022|News, News Releases, 2022|

SHINE and Department of Energy Sign First-ever Contracts Under Uranium Lease and Take-back Program for Molybdenum-99

Vital medical radioisotope used in over 40,000 medical diagnostic procedures [...]

2022-03-09T09:23:37-06:00January 6, 2022|News, News Releases, 2022|

SHINE Medical Technologies Closes $150-million Series C-5 Financing

SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing. Koch Disruptive Technologies (KDT) led the round, which also included participation by Fidelity Management & Research Company, Baillie Gifford and other new and current investors.

2021-12-17T17:35:59-06:00June 28, 2021|News, News Releases, 2021|

SHINE announces weathertight production facility

SHINE Technologies announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building has been certified as weathertight, a major milestone with significance for SHINE.

2021-12-17T17:37:36-06:00March 25, 2021|News, News Releases, 2021|

SHINE closes $80-million

SHINE Medical Technologies LLC, a nuclear technology company focused on becoming the world’s leading producer of medical isotopes, announced today that it has closed an $80-million Series C financing. Fidelity Management and Research Company LLC was the largest investor in the round, which also included participation from other new investors and the company’s current investors.

2021-12-16T20:07:17-06:00September 3, 2020|News, News Releases, 2020|

NRC issues review schedule for SHINE application

SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) expects to make a final determination regarding the issuance of an operating license to SHINE by October 2021. SHINE’s application for a license to operate the medical isotope production facility that it is building in Janesville, Wis., was accepted and docketed by the NRC last October.

2021-12-17T17:40:23-06:00May 11, 2020|News, News Releases, 2020|

NRC Accepts SHINE Application

SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) has begun its detailed technical review of SHINE’s application to operate the medical isotope production facility the company is building in Janesville, Wis.

2021-12-17T17:41:25-06:00October 15, 2019|News, News Releases, Archived, 2019|

SHINE & Phoenix Combine for World Record

Phoenix and SHINE Achieve New World Record for Strongest Nuclear Fusion Reaction in a Steady-State System. Leading nuclear technology companies collaborating to help turn nuclear weapons into medicine and help a billion patients. Breakthrough has potential to transform medical isotope production, solve a global health care shortage, provide a stepping stone to cleaner, safer, more abundant energy

2021-12-17T17:42:35-06:00October 2, 2019|News, News Releases, Archived, Neutron Generators, 2019|
Go to Top